NCT06770439View on ClinicalTrials.gov

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Advanced Pancreatic Cancers
Interventions
DRUG

IBI343

IBI343 is a recombinant anti-tight junction protein 18.2 monoclonal antibody - ecotecan conjugate

DRUG

Gemcitabine+Albumin-bound paclitaxel

Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer

Trial Locations (2)

310000

NOT_YET_RECRUITING

First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou

RECRUITING

the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER